

February 10, 2023

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of an Independent Director of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board of the Company at its Meeting held today has approved the appointment of Mrs. Vijayalakshmi Rajaram Iyer (DIN: 05242960) as an Additional Director designated as Non-Executive - Independent, not liable to retire by rotation, effective today i.e. February 10, 2023.

Further, the Board has approved seeking necessary approval of the Members of the Company pursuant to the provisions of Regulation 17(1C) of SEBI Listing Regulations and other applicable provisions, by way of postal ballot.

Pursuant to the BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/24 dated June 20, 2018, Mrs. Vijayalakshmi Rajaram Iyer is not debarred from holding the office of Director by virtue of any order of the Securities and Exchange Board of India or any other such authority.

Details in respect of the said appointment are enclosed herewith as **Annexure A**.

You are requested to take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Harish Kuber

Company Secretary & Compliance Officer

Encl: As above

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sl.	Particulars	Details
1.	Name of the Director	Mrs. Vijayalakshmi Rajaram Iyer
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
3.	Date of appointment/ cessation (as applicable) & term of appointment;	Based on the recommendations of the Nomination and Remuneration Committee, the Board of the Company considered and approved the appointment of Mrs. Vijayalakshmi Rajaram Iyer (DIN: 05242960) as an Additional Director designated as Non-Executive Independent Director, subject to approval of the shareholders of the Company for a term of 5 (five) years with effect from February 10, 2023.
4.	Brief profile (in case of appointment);	<p>Mrs. Vijayalakshmi graduated from M.L. Dahanukar College of Commerce and did her post-graduation from Sydenham College of Commerce, Mumbai. She is also a certified associate of the Indian Institute of Banking and Finance. She has nearly four decades of experience in the banking and finance sector in India.</p> <p>She retired as the chairman and managing director of Bank of India in May 2015 where she played an instrumental role in structuring it as an umbrella institution offering all kinds of banking and financial services. She also served as member (finance & investment) at IRDAI from 2015 to 2017 where she played a significant role in the introduction and amendment of various regulations related to, inter alia, finance and accounts, corporate governance, mergers and acquisition, registration of new insurance companies and exposure of management.</p>
5.	Disclosure of relationships between directors (in case of appointment of a director)	None

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com